According to Zacks, “Dova Pharmaceuticals, Inc. is a pharmaceutical company. It focuses on acquiring, developing and commercializing drug candidates for thrombocytopenia diseases. The company’s drug candidate includes avatrombopag, an orally administered thrombopoietin receptor agonist which are in clinical stage. Dova Pharmaceuticals, Inc. is based in Durham, North Carolina. “
DOVA has been the subject of a number of other research reports. Evercore ISI raised Dova Pharmaceuticals from an in-line rating to an outperform rating and set a $15.00 target price for the company in a research report on Monday, July 1st. HC Wainwright boosted their price target on Dova Pharmaceuticals from $18.00 to $39.00 and gave the company a buy rating in a research note on Thursday, June 27th. JPMorgan Chase & Co. boosted their price target on Dova Pharmaceuticals from $13.00 to $15.00 and gave the company an underweight rating in a research note on Friday, July 12th. Wedbush assumed coverage on Dova Pharmaceuticals in a research note on Wednesday, May 22nd. They set an outperform rating and a $19.00 price target for the company. Finally, BidaskClub upgraded Dova Pharmaceuticals from a buy rating to a strong-buy rating in a research note on Thursday, August 1st. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and six have given a buy rating to the company’s stock. The company has an average rating of Buy and a consensus target price of $27.13.
Shares of NASDAQ:DOVA opened at $14.52 on Thursday. Dova Pharmaceuticals has a fifty-two week low of $5.62 and a fifty-two week high of $26.49. The business has a 50-day simple moving average of $15.96 and a two-hundred day simple moving average of $10.69. The company has a debt-to-equity ratio of 0.41, a current ratio of 5.64 and a quick ratio of 5.37.
Dova Pharmaceuticals (NASDAQ:DOVA) last issued its earnings results on Tuesday, August 6th. The company reported ($0.60) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.57) by ($0.03). Dova Pharmaceuticals had a negative return on equity of 101.60% and a negative net margin of 544.09%. The business had revenue of $3.52 million during the quarter, compared to analysts’ expectations of $5.63 million. Research analysts expect that Dova Pharmaceuticals will post -2.37 earnings per share for the current fiscal year.
In other news, Director Paul B. Manning purchased 28,062 shares of the business’s stock in a transaction on Friday, August 9th. The stock was acquired at an average cost of $15.87 per share, for a total transaction of $445,343.94. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, major shareholder Life Sciences Maste Perceptive purchased 427,209 shares of the business’s stock in a transaction on Friday, June 28th. The shares were purchased at an average price of $13.35 per share, with a total value of $5,703,240.15. The disclosure for this purchase can be found here. Over the last 90 days, insiders have acquired 610,916 shares of company stock valued at $8,689,169 and have sold 27,807 shares valued at $422,464. Insiders own 60.30% of the company’s stock.
Several large investors have recently made changes to their positions in DOVA. Perceptive Advisors LLC grew its stake in shares of Dova Pharmaceuticals by 13.7% during the 2nd quarter. Perceptive Advisors LLC now owns 3,553,060 shares of the company’s stock valued at $50,098,000 after acquiring an additional 427,209 shares during the period. Sanders Morris Harris LLC bought a new position in shares of Dova Pharmaceuticals during the 1st quarter valued at approximately $2,507,000. Vanguard Group Inc. grew its stake in shares of Dova Pharmaceuticals by 34.1% during the 2nd quarter. Vanguard Group Inc. now owns 691,318 shares of the company’s stock valued at $9,748,000 after acquiring an additional 175,605 shares during the period. Morgan Stanley grew its stake in shares of Dova Pharmaceuticals by 102.2% during the 2nd quarter. Morgan Stanley now owns 325,998 shares of the company’s stock valued at $4,596,000 after acquiring an additional 164,761 shares during the period. Finally, Sio Capital Management LLC bought a new position in shares of Dova Pharmaceuticals during the 2nd quarter valued at approximately $1,905,000. Institutional investors own 27.30% of the company’s stock.
About Dova Pharmaceuticals
Dova Pharmaceuticals, Inc, a pharmaceutical company, focuses on acquiring, developing, and commercializing drug candidates for thrombocytopenia disease. The company's lead product candidate is DOPTELET that is indicated for the treatment of thrombocytopenia in adult patients with chronic liver disease scheduled to undergo a procedure.
Further Reading: What is the Quick Ratio?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Dova Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dova Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.